Copyright Reports & Markets. All rights reserved.

Global (United States, European Union and China) LATAM Adalimumab Market Research Report 2019-2025

Request for Sample of this report
Buy now

Table of Contents

    1 Report Overview

    • 1.1 Study Scope
    • 1.2 Major Manufacturers Covered in This Report
    • 1.3 Market Segment by Type
      • 1.3.1 Global LATAM Adalimumab Market Size Growth Rate by Type (2019-2025)
      • 1.3.2 Oral Type
      • 1.3.3 Injection Type
    • 1.4 Market Segment by Application
      • 1.4.1 Global LATAM Adalimumab Market Share by Application (2019-2025)
      • 1.4.2 Rheumatoid Arthritis
      • 1.4.3 Psoriasis
      • 1.4.4 Crohn’s Disease
      • 1.4.5 Ulcerative Colitis
      • 1.4.6 Others
    • 1.5 Study Objectives
    • 1.6 Years Considered

    2 Global Growth Trends

    • 2.1 Global LATAM Adalimumab Market Size
      • 2.1.1 Global LATAM Adalimumab Revenue 2014-2025
      • 2.1.2 Global LATAM Adalimumab Sales 2014-2025
    • 2.2 LATAM Adalimumab Growth Rate by Regions
      • 2.2.1 Global LATAM Adalimumab Sales by Regions 2014-2019
      • 2.2.2 Global LATAM Adalimumab Revenue by Regions 2014-2019
    • 2.3 Industry Trends
      • 2.3.1 Market Top Trends
      • 2.3.2 Market Drivers

    3 Market Share by Manufacturers

    • 3.1 LATAM Adalimumab Sales by Manufacturers
      • 3.1.1 LATAM Adalimumab Sales by Manufacturers 2014-2019
      • 3.1.2 LATAM Adalimumab Sales Market Share by Manufacturers 2014-2019
    • 3.2 Revenue by Manufacturers
      • 3.2.1 LATAM Adalimumab Revenue by Manufacturers (2014-2019)
      • 3.2.2 LATAM Adalimumab Revenue Share by Manufacturers (2014-2019)
      • 3.2.3 Global LATAM Adalimumab Market Concentration Ratio (CR5 and HHI)
    • 3.3 LATAM Adalimumab Price by Manufacturers
    • 3.4 Key Manufacturers LATAM Adalimumab Plants/Factories Distribution and Area Served
    • 3.5 Date of Key Manufacturers Enter into LATAM Adalimumab Market
    • 3.6 Key Manufacturers LATAM Adalimumab Product Offered
    • 3.7 Mergers & Acquisitions, Expansion Plans

    4 Market Size by Type

    • 4.1 Sales and Revenue for Each Type
      • 4.1.1 Oral Type Sales and Revenue (2014-2019)
      • 4.1.2 Injection Type Sales and Revenue (2014-2019)
    • 4.2 Global LATAM Adalimumab Sales Market Share by Type
    • 4.3 Global LATAM Adalimumab Revenue Market Share by Type
    • 4.4 LATAM Adalimumab Price by Type

    5 Market Size by Application

    • 5.1 Overview
    • 5.2 Global LATAM Adalimumab Sales by Application

    6 United States

    • 6.1 United States LATAM Adalimumab Breakdown Data by Company
    • 6.2 United States LATAM Adalimumab Breakdown Data by Type
    • 6.3 United States LATAM Adalimumab Breakdown Data by Application

    7 European Union

    • 7.1 European Union LATAM Adalimumab Breakdown Data by Company
    • 7.2 European Union LATAM Adalimumab Breakdown Data by Type
    • 7.3 European Union LATAM Adalimumab Breakdown Data by Application

    8 China

    • 8.1 China LATAM Adalimumab Breakdown Data by Company
    • 8.2 China LATAM Adalimumab Breakdown Data by Type
    • 8.3 China LATAM Adalimumab Breakdown Data by Application

    9 Rest of World

    • 9.1 Rest of World LATAM Adalimumab Breakdown Data by Company
    • 9.2 Rest of World LATAM Adalimumab Breakdown Data by Type
    • 9.3 Rest of World LATAM Adalimumab Breakdown Data by Application
    • 9.4 Rest of World LATAM Adalimumab Breakdown Data by Countries
      • 9.4.1 Rest of World LATAM Adalimumab Sales by Countries
      • 9.4.2 Rest of World LATAM Adalimumab Revenue by Countries
      • 9.4.3 Japan
      • 9.4.4 Korea
      • 9.4.5 India
      • 9.4.6 Southeast Asia

    10 Company Profiles

    • 10.1 AbbVie, Inc.
      • 10.1.1 AbbVie, Inc. Company Details
      • 10.1.2 Company Description and Business Overview
      • 10.1.3 Sales, Revenue and Market Share of LATAM Adalimumab
      • 10.1.4 LATAM Adalimumab Product Introduction
      • 10.1.5 AbbVie, Inc. Recent Development
    • 10.2 Amgen, Inc.
      • 10.2.1 Amgen, Inc. Company Details
      • 10.2.2 Company Description and Business Overview
      • 10.2.3 Sales, Revenue and Market Share of LATAM Adalimumab
      • 10.2.4 LATAM Adalimumab Product Introduction
      • 10.2.5 Amgen, Inc. Recent Development
    • 10.3 Boehringer Ingelheim GmbH
      • 10.3.1 Boehringer Ingelheim GmbH Company Details
      • 10.3.2 Company Description and Business Overview
      • 10.3.3 Sales, Revenue and Market Share of LATAM Adalimumab
      • 10.3.4 LATAM Adalimumab Product Introduction
      • 10.3.5 Boehringer Ingelheim GmbH Recent Development
    • 10.4 Eisai Co., Ltd.
      • 10.4.1 Eisai Co., Ltd. Company Details
      • 10.4.2 Company Description and Business Overview
      • 10.4.3 Sales, Revenue and Market Share of LATAM Adalimumab
      • 10.4.4 LATAM Adalimumab Product Introduction
      • 10.4.5 Eisai Co., Ltd. Recent Development
    • 10.5 Mylan N.V.
      • 10.5.1 Mylan N.V. Company Details
      • 10.5.2 Company Description and Business Overview
      • 10.5.3 Sales, Revenue and Market Share of LATAM Adalimumab
      • 10.5.4 LATAM Adalimumab Product Introduction
      • 10.5.5 Mylan N.V. Recent Development
    • 10.6 Novartis AG
      • 10.6.1 Novartis AG Company Details
      • 10.6.2 Company Description and Business Overview
      • 10.6.3 Sales, Revenue and Market Share of LATAM Adalimumab
      • 10.6.4 LATAM Adalimumab Product Introduction
      • 10.6.5 Novartis AG Recent Development
    • 10.7 Pfizer, Inc.
      • 10.7.1 Pfizer, Inc. Company Details
      • 10.7.2 Company Description and Business Overview
      • 10.7.3 Sales, Revenue and Market Share of LATAM Adalimumab
      • 10.7.4 LATAM Adalimumab Product Introduction
      • 10.7.5 Pfizer, Inc. Recent Development

    11 Value Chain and Sales Channels Analysis

    • 11.1 Value Chain Analysis
    • 11.2 Sales Channels Analysis
      • 11.2.1 LATAM Adalimumab Sales Channels
      • 11.2.2 LATAM Adalimumab Distributors
    • 11.3 LATAM Adalimumab Customers

    12 Market Forecast

    • 12.1 Global LATAM Adalimumab Sales and Revenue Forecast 2019-2025
    • 12.2 Global LATAM Adalimumab Sales Forecast by Type
    • 12.3 Global LATAM Adalimumab Sales Forecast by Application
    • 12.4 LATAM Adalimumab Forecast by Regions
      • 12.4.1 Global LATAM Adalimumab Sales Forecast by Regions 2019-2025
      • 12.4.2 Global LATAM Adalimumab Revenue Forecast by Regions 2019-2025
    • 12.5 United States Market Forecast
    • 12.6 European Union Market Forecast
    • 12.7 China Market Forecast
    • 12.8 Rest of World
      • 12.8.1 Japan
      • 12.8.2 Korea
      • 12.8.3 India

    13 Research Findings and Conclusion

      14 Appendix

      • 14.1 Research Methodology
        • 14.1.1 Methodology/Research Approach
          • 14.1.1.1 Research Programs/Design
          • 14.1.1.2 Market Size Estimation
          • 14.1.1.3 Market Breakdown and Data Triangulation
        • 14.1.2 Data Source
          • 14.1.2.1 Secondary Sources
          • 14.1.2.2 Primary Sources
      • 14.2 Author Details

      Adalimumab was first approved in the U.S. for the treatment of aforementioned medical conditions. Currently, this is marketed in more than 60 countries. However, owing to the biologic nature of the drug, it results in high cost and low accessibility in emerging economies such as LATAM and Asia Pacific. On the other hand, with the probable entry of the adalimumab biosimilars post the patent expiry the low costs up to less than 25% to 35% of the originator drugs will boost the uptake and prescription of adalimumab for the treatment of above mentioned medical conditions.
      Consistent technological sophistications in development of biosimilar followed by increasing incidence and prevalence of various medical conditions have rendered encouraging growth opportunities for various biological drugs and other innovative biopharmaceuticals. The LATAM adalimumab market by application has been categorized on the basis of the usage of adalimumab for treatment of various medical conditions.
      In 2019, the market size of LATAM Adalimumab is xx million US$ and it will reach xx million US$ in 2025, growing at a CAGR of xx% from 2019; while in China, the market size is valued at xx million US$ and will increase to xx million US$ in 2025, with a CAGR of xx% during forecast period.
      In this report, 2018 has been considered as the base year and 2019 to 2025 as the forecast period to estimate the market size for LATAM Adalimumab.

      This report studies the global market size of LATAM Adalimumab, especially focuses on the key regions like United States, European Union, China, and other regions (Japan, Korea, India and Southeast Asia).
      This study presents the LATAM Adalimumab sales volume, revenue, market share and growth rate for each key company, and also covers the breakdown data (sales, revenue and market share) by regions, type and applications. history breakdown data from 2014 to 2019, and forecast to 2025.
      For top companies in United States, European Union and China, this report investigates and analyzes the production, value, price, market share and growth rate for the top manufacturers, key data from 2014 to 2019.

      In global market, the following companies are covered:
      AbbVie, Inc.
      Amgen, Inc.
      Boehringer Ingelheim GmbH
      Eisai Co., Ltd.
      Mylan N.V.
      Novartis AG
      Pfizer, Inc.
      ...

      Market Segment by Product Type
      Oral Type
      Injection Type

      Market Segment by Application
      Rheumatoid Arthritis
      Psoriasis
      Crohn’s Disease
      Ulcerative Colitis
      Others

      Key Regions split in this report: breakdown data for each region.
      United States
      China
      European Union
      Rest of World (Japan, Korea, India and Southeast Asia)

      The study objectives are:
      To analyze and research the LATAM Adalimumab status and future forecast in United States, European Union and China, involving sales, value (revenue), growth rate (CAGR), market share, historical and forecast.
      To present the key LATAM Adalimumab manufacturers, presenting the sales, revenue, market share, and recent development for key players.
      To split the breakdown data by regions, type, companies and applications
      To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints and risks.
      To identify significant trends, drivers, influence factors in global and regions
      To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market

      In this study, the years considered to estimate the market size of LATAM Adalimumab are as follows:
      History Year: 2014-2018
      Base Year: 2018
      Estimated Year: 2019
      Forecast Year 2019 to 2025

      Buy now